This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
The cause of the interaction is not known.
What might happen:
This combination of medicines may cause life-threatening effects to your heart.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these two medicines together. Let your doctor know right away if you notice an irregular heartbeat or have any dizziness or fainting episodes. Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Cipro (ciprofloxacin hydrochloride) US prescribing information. Bayer Corporation July, 2017.
2.Tequin (gatifloxacin) US prescribing information. Bristol-Myers Squibb Company January, 2006.
3.Factive (gemifloxacin mesylate) US prescribing information. Merus Labs International, Inc. May, 2016.
4.Levaquin (levofloxacin) US prescribing information. Janssen Pharmaceuticals, Inc. July, 2016.
5.Maxaquin (lomefloxacin hydrochloride) US prescribing information. Pfizer Inc. January, 2005.
6.Avelox (moxifloxacin hydrochloride) US prescribing information. Bayer Pharmaceuticals Corporation July, 2016.
7.NegGram (nalidixic acid) US prescribing information. Sanofi-Synthelabo, Inc. November, 2012.
8.Noroxin (norfloxacin) US prescribing information. Merck & Co., Inc. July, 2016.
9.Floxin (ofloxacin) US prescribing information. Ortho-McNeil Pharmaceutical, Inc. February, 2011.
10.Maxa JL, Hebeler RF, Adeeko MA. Torsades de pointes following concurrent amiodarone and levofloxacin therapy. Proc (Bayl Univ Med Cent) 2006 Oct; 19(4):345-6.
11.Prabhakar M, Krahn AD. Ciprofloxacin-induced acquired long QT syndrome. Heart Rhythm 2004 Nov;1(5):624-6.
12.Bleske BE, Carver PL, Annesley TM, Bleske JR, Morady F. The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. J Clin Pharmacol 1990 Oct;30(10):911-5.
13.Bauer LA, Black DJ, Lill JS, Garrison J, Raisys VA, Hooton TM. Levofloxacin and ciprofloxacin decrease procainamide and N-acetylprocainamide renal clearances. Antimicrob Agents Chemother 2005 Apr;49(4):1649-51.
14.Martin DE, Shen J, Griener J, Raasch R, Patterson JH, Cascio W. Effects of ofloxacin on the pharmacokinetics and pharmacodynamics of procainamide. J Clin Pharmacol 1996 Jan;36(1):85-91.
15.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
16.Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, Middleton B, Bates DW. High-priority drug-drug interactions for use in electronic health records. J Am Med Inform Assoc 2012 Sep-Oct; 19(5):735-43.